12 As with other diseases that are characterized by acute attacks, such as asthma, the burden of HAE is not only economic but also impacts the patient’s quality of life, education, relationships ...

RESEARCH TRIANGLE PARK, N.C. - BioCryst Pharmaceuticals , Inc. (NASDAQ:BCRX), a biotechnology company with impressive revenue growth of nearly 30% over the last twelve months, has announced that ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved CSL’s Andembry (garadacimab) to prevent ...

At only 27 years old, Daniela Powers felt like she was dying. What began as unexplained rashes exploded into a debilitating ...

Shire noted that the study was representative of the full HAE disease spectrum. Overall, 52% of the study’s 125 patients experienced three or more attacks per month at baseline, 65% of patients ...

HAE is a rare genetic disease that affects approximately 8000 patients in the US, although Shire believes only 3,500 of these patients actively manage their disease. HAE is characterised by ...

A total of 82 patients (41.4%) began lanadelumab because of a lack of response to other HAE prophylactic therapy, 42 patients (21.2%) due to a lack of disease control before on-demand therapy and ...